

Optimal Settings for OMOP 2011-2012 Research

Data	Acute kidney injury	Acute liver injury	Acute myocardial infarction	GI Bleed
MDCR	Observational screening OS: 401002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 401002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 407002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: First occurrence Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 402002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: Yes Control period: Length of exposure + 30d Include index date in control period: Yes
CCAE	Observational screening OS: 404002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: Yes	Observational screening OS: 403002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: Yes Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 408013 Study design: Self-controlled cohort Exposures to include: First occurrence Outcomes to include: First occurrence after exposure Time-at-risk: All time post-exposure start Include index date in time-at-risk: No Control period: All time prior to exposure start Include index date in control period: No	Self-controlled case series SCCS: 1931010 Outcomes to include: All occurrences Prior distribution: normal Variance of the prior: Determined through cross-validation Time-at-risk: All time post-exposure start Include index date in time-at-risk: No Apply multivariate adjustment on all drugs: No Required observation time: 180d
MDCD	Observational screening OS: 408013 Study design: Self-controlled cohort Exposures to include: First occurrence Outcomes to include: First occurrence after exposure Time-at-risk: All time post-exposure start Include index date in time-at-risk: No Control period: All time prior to exposure start Include index date in control period: No	Observational screening OS: 409013 Study design: Self-controlled cohort Exposures to include: First occurrence Outcomes to include: First occurrence Time-at-risk: All time post-exposure start Include index date in time-at-risk: No Control period: All time prior to exposure start Include index date in control period: No	Observational screening OS: 407004 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: First occurrence Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: 365d prior to exposure start Include index date in control period: No	Observational screening OS: 401004 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: 365d prior to exposure start Include index date in control period: No
MSLR	Self-controlled case series SCCS: 1939009 Outcomes to include: All occurrences Prior distribution: Laplace Variance of the prior: Determined through cross-validation Time-at-risk: All time post-exposure start Include index date in time-at-risk: Yes Apply multivariate adjustment on all drugs: Yes Required observation time: None	Observational screening OS: 406002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: First occurrence after exposure Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 403002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: Yes Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 403002 Study design: Self-controlled cohort Exposures to include: All occurrences Outcomes to include: All occurrences Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: Yes Control period: Length of exposure + 30d Include index date in control period: No
GE	Observational screening OS: 409002 Study design: Self-controlled cohort Exposures to include: First occurrence Outcomes to include: First occurrence Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Observational screening OS: 409002 Study design: Self-controlled cohort Exposures to include: First occurrence Outcomes to include: First occurrence Time-at-risk: Length of exposure + 30d Include index date in time-at-risk: No Control period: Length of exposure + 30d Include index date in control period: No	Temporal pattern discovery ICTPD: 3016001 Control period: -1080d to -361d before exposure start Time-at-risk: 60d from exposure start Use control period in expected calculation: Yes Use 1mo prior to exposure in expected calculation: Yes Use 1d prior to exposure in expected calculation: No	Temporal pattern discovery ICTPD: 3034001 Control period: -810d to -361d before exposure start Time-at-risk: 60d from exposure start Use control period in expected calculation: Yes Use 1mo prior to exposure in expected calculation: No Use 1d prior to exposure in expected calculation: Yes